ABN 53 075 582 740

ASX ANNOUNCEMENT
24 June 2016

ENROLMENT COMPLETED IN BNC210 GENERALISED ANXIETY DISORDER TRIAL

ADELAIDE, Australia, 24 June 2016: Bionomics Limited (ASX:BNO; OTCQX:BNOEF), a biopharmaceutical company focused on discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, today announced that it has completed enrolment in its UK-based Phase II trial of BNC210 in Generalised Anxiety Disorder (GAD).

The clinical trial is a double-blinded, placebo and lorazepam-controlled, four-way crossover single-centre study with patients suffering from untreated GAD. The capacity of BNC210 to engage brain systems relevant to anxiety is being evaluated. Endpoints include both significant changes in cerebral perfusion using arterial spin labeling (ASL) and in emotional task-related brain activity using the emotional faces task during functional Magnetic Resonance Imaging (fMRI). The study is being conducted at The Institute of Psychiatry, Psychology & Neuroscience at King's College in London.

"Timely completion of enrolment is an important milestone for this clinical trial with data expected to be released next quarter" said Dr. Deborah Rathjen, CEO & Managing Director of Bionomics.

"Bionomics continues to focus on the discovery and development of innovative therapeutics such as BNC210, which we believe presents a significant opportunity to reduce the impact of anxiety both on sufferers and the wider community. BNC210 possesses significant potential in meeting a currently unmet medical need for fast-acting anxiolytic agents that do not carry the side-effects of existing treatments such as sedation, addiction and negative effects on memory and coordination."

Bionomics is also in the process of initiating a Phase II trial of BNC210 in Post-Traumatic Stress Disorder (PTSD) with a start date anticipated in H1 2016.

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia
Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US
Stern IR, Inc.
Beth Del Giacco
+1 212 362 1200
beth@sternir.com

About BNC210
BNC210 is a first-in-class compound for the treatment of anxiety that lacks the side effect profile of current therapies such as benzodiazepines, selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors. BNC210 works by negative allosteric modulation of the alpha 7 nicotinic acetylcholine receptor which is a key target for anxiety.

About Bionomics Limited
Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.

Clinical Trial Appendix

STUDY REFERENCE	BNC210.006
STUDY TITLE	A randomised, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured by functional magnetic resonance imaging in adults with Generalised Anxiety Disorder (GAD).
PRIMARY OBJECTIVES	Primary objectives: (A) To determine whether BNC210 causes significant changes in cerebral perfusion using Arterial Spin Labelling in the resting state. (B) To determine whether BNC210 causes significant changes in task-related brain activity using the emotional faces task during functional magnetic resonance imaging (fMRI).
SECONDARY & EXPORATORY OBJECTIVES	Secondary objectives: - To determine the effect of BNC210 on defensive behaviour. - To determine whether BNC210 alters affective self-report in a way that is consistent with reduced anxiety. - To contribute safety and tolerability information on BNC210. Exploratory objective To determine the correlation between BNC210-related brain activity changes and affective self-report.
BLINDING STATUS	Double-blinded
TREATMENT METHOD	Randomised, four-way crossover, with the effects of two dose levels of BNC210 (300 mg and 2000 mg) being compared to those of placebo, and 1.5 mg lorazepam used as a positive control.
TRIAL SUBJECT NUMBER	A sufficient number of subjects will be enrolled to allow 24 completing subjects.
CONTROL GROUP	Placebo and 1.5 mg lorazepam Positive Control
SUBJECT SELECTION CRITERIA	Male or female volunteers who are un-medicated but meet the criteria for Generalised Anxiety Disorder
TRIAL LOCATION	The Institute of Psychiatry, Psychology & Neuroscience, King's College, London
ADDITIONAL INFORMATION	Pharmacodynamic evaluation Brain activity will be assessed by fMRI under resting condition where functional connectivity and Continuous Arterial Spin Labelling as a measure of cerebral blood flow will be collected. Functional MRI will also be used during different tasks: an emotional faces task and a behavioural task (Joystick Operated Runaway Task). The Spielberger State-Trait Anxiety inventory and a subjective scale assessment will also be used as outcome measures.
CLINICAL TRIAL HISTORY	BNC210 has been evaluated in six clinical trials and 192 subjects to date 1. BNC210.001: Single Ascending Doses Study - Australia 2. BNC210.002: Fed and Fasted Study - Australia 3. BNC210.003: Lorazepam Comparison and EEG Study, cognition as primary end point - France 4. BNC210.004: CCK Challenge - France 5. Single Ascending Doses Study – USA 6. BNC210.005: Multiple Ascending Doses Study - France